- TheStreet.com•40 minutes ago
The pharma giant lost its third trial over claims that its talcum powder can cause ovarian cancer, but share prices remain unchanged.
- Associated Press•48 minutes ago
TRENTON, N.J. (AP) — For the third time, Johnson & Johnson has been hit with a multimillion-dollar jury verdict over whether the talc in its iconic baby powder causes ovarian cancer when applied regularly for feminine hygiene.
Johnson & Johnson (JNJ)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||115.27 x 300|
|Ask||115.30 x 400|
|Day's Range||114.57 - 115.91|
|52wk Range||94.28 - 126.07|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||20.25|
|Avg Vol (3m)||6,196,280|
|Dividend & Yield||3.20 (2.79%)|